Ray Dalio’s Nektar Therapeutics NKTR Stock Holding History

Ray Dalio’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-738	Closed	-$221K	–	748
2021 Q1	$221K	Buy	+738	New	+$230K	﹤0.01%	440

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Ray Dalio's NKTR Position: Q2 2021 in Review

Ray Dalio sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 738 shares — an estimated $221K sold.

Ray Dalio first reported a position in NKTR in Q1 2021 and held it in 1 quarter. The position peaked at $221K in Q1 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

Ray Dalio reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
Ray Dalio sold 738 Nektar Therapeutics shares in Q2 2021, an estimated $221K.
Ray Dalio first reported a position in Nektar Therapeutics in Q1 2021 and held it in 1 quarter.
Ray Dalio's Nektar Therapeutics position peaked at $221K in Q1 2021.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Bridgewater Associates's 13F filing for Q2 2021, filed 13 Aug 2021.